My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 446

    1.

    Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.

    Harrity T, Farrelly D, Tieman A, Chu C, Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, Wang W, Zhang H, Fenderson W, Chen S, Devasthale P, Jeon Y, Seethala R, Yang WP, Ren J, Zhou M, Ryono D, Biller S, Mookhtiar KA, Wetterau J, Gregg R, Cheng PT, Hariharan N.

    Diabetes. 2006 Jan;55(1):240-8.PMID: 16380499 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.

    Tozzo E, Ponticiello R, Swartz J, Farrelly D, Zebo R, Welzel G, Egan D, Kunselman L, Peters A, Gu L, French M, Chen S, Devasthale P, Janovitz E, Staal A, Harrity T, Belder R, Cheng PT, Whaley J, Taylor S, Hariharan N.

    J Pharmacol Exp Ther. 2007 Apr;321(1):107-15. Epub 2007 Jan 26.PMID: 17259449 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

    Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

    4.

    Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

    Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

    Devasthale PV, Chen S, Jeon Y, Qu F, Shao C, Wang W, Zhang H, Cap M, Farrelly D, Golla R, Grover G, Harrity T, Ma Z, Moore L, Ren J, Seethala R, Cheng L, Sleph P, Sun W, Tieman A, Wetterau JR, Doweyko A, Chandrasena G, Chang SY, Humphreys WG, Sasseville VG, Biller SA, Ryono DE, Selan F, Hariharan N, Cheng PT.

    J Med Chem. 2005 Mar 24;48(6):2248-50.PMID: 15771468 [PubMed - indexed for MEDLINE]Related articles

    6.

    Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.

    Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I.

    J Pharmacol Sci. 2008 Sep;108(1):40-8. Epub 2008 Sep 6.PMID: 18776709 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

    Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.

    Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.PMID: 15831517 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.

    Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S.

    Br J Pharmacol. 2009 Jul;157(5):724-35. Epub 2009 May 5.PMID: 19422369 [PubMed - indexed for MEDLINE]Related articles

    9.

    Transgenic expression of a mutated cyclin-dependent kinase 4 (CDK4/R24C) in pancreatic beta-cells prevents progression of diabetes in db/db mice.

    Miyawaki K, Inoue H, Keshavarz P, Mizuta K, Sato A, Sakamoto Y, Moritani M, Kunika K, Tanahashi T, Itakura M.

    Diabetes Res Clin Pract. 2008 Oct;82(1):33-41. Epub 2008 Aug 3.PMID: 18678431 [PubMed - indexed for MEDLINE]Related articles

    10.

    A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

    Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

    Diabetes. 2002 Apr;51(4):1083-7.PMID: 11916929 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.

    Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK.

    Diabetes. 2008 Mar;57(3):737-45. Epub 2007 Dec 7.PMID: 18065517 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

    Br J Pharmacol. 2009 Jun;157(3):415-26. Epub 2009 Apr 3.PMID: 19371350 [PubMed - indexed for MEDLINE]Related articles

    13.

    Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

    Tenenbaum A, Motro M, Fisman EZ.

    Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.PMID: 16168052 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

    Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L, Priyadarsiny P, Khattar SK, Bora RS, Saini KS, Bansal VS.

    Br J Pharmacol. 2007 Feb;150(4):480-7. Epub 2007 Jan 8.PMID: 17211457 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.

    Cox SL.

    Drugs Today (Barc). 2005 Sep;41(9):579-87. Review.PMID: 16341289 [PubMed - indexed for MEDLINE]Related articles

    16.

    Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.

    Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW.

    J Pharmacol Exp Ther. 2009 May;329(2):571-9. Epub 2009 Feb 12.PMID: 19221061 [PubMed - indexed for MEDLINE]Related articles

    17.

    Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.

    Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S.

    Metabolism. 2004 Apr;53(4):488-94.PMID: 15045697 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.

    Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A.

    J Pharm Pharmacol. 2008 Sep;60(9):1167-73.PMID: 18718120 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice.

    Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S.

    Endocr J. 2005 Aug;52(4):427-33.PMID: 16127210 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

    Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

    Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity